Zhang Qiang, Li Xu, Cui Kasa, Liu Cheng, Wu Mingzhi, Prochownik Edward V, Li Youjun
Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, 430072, Wuhan, China.
Medical Research Institute, School of Medicine, Wuhan University, 430071, Wuhan, China.
Cell Death Differ. 2020 Feb;27(2):420-433. doi: 10.1038/s41418-019-0363-0. Epub 2019 Jun 11.
c-Myc (Myc) is a master transcription factor that is often deregulated and highly expressed by at least 50% of cancers. In many cases, Myc protein levels correlate with resistance to therapy and poor prognosis. However, effective direct inhibition of Myc by pharmacologic approaches has remained unachievable. Here, we identify MAP3K13 as a positive regulator of Myc to promote tumor development. Our findings show that MAP3K13 upregulation is predictive of poor outcomes in patients with hepatocellular carcinoma (HCC). Mechanistically, MAP3K13 phosphorylates the E3 ubiquitin ligase TRIM25 at Ser to decrease its polyubiquitination and proteasomal degradation. This newly stabilized TRIM25 then directly ubiquitinates Lys of FBXW7α, a core subunit of the SKP1-Cullin-F-box (SCF) ubiquitin ligase complex involved in Myc ubiquitination, thereby stabilizing Myc. Together, these results reveal a novel regulatory pathway that supervises Myc protein stability via the MAP3K13-TRIM25-FBXW7α signaling axis. In addition, they provide a potential therapeutic target in Myc over-expressing human cancers.
c-Myc(Myc)是一种主要的转录因子,在至少50%的癌症中经常失调并高表达。在许多情况下,Myc蛋白水平与治疗耐药性和不良预后相关。然而,通过药理学方法有效直接抑制Myc仍然无法实现。在此,我们确定丝裂原活化蛋白激酶激酶激酶13(MAP3K13)是Myc的一个正向调节因子,可促进肿瘤发展。我们的研究结果表明,MAP3K13上调可预测肝细胞癌(HCC)患者的不良预后。从机制上讲,MAP3K13在丝氨酸位点磷酸化E3泛素连接酶TRIM25,以减少其多聚泛素化和蛋白酶体降解。这种新稳定的TRIM25随后直接泛素化FBXW7α的赖氨酸,FBXW7α是参与Myc泛素化的SKP1- Culli n-F盒(SCF)泛素连接酶复合物的核心亚基,从而稳定Myc。总之,这些结果揭示了一条通过MAP3K13-TRIM25-FBXW7α信号轴监督Myc蛋白稳定性的新调控途径。此外,它们为Myc过表达的人类癌症提供了一个潜在的治疗靶点。